High Potency APIs /HPAPI Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech, moAB, Vaccines, Recombinant Proteins), Manufacturer (Captive and Merchant), Therapy (Oncology, Glaucoma, Hormonal Imbalance) - Global Forecasts to 2023

Table of Contents

1 INTRODUCTION 21

1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 STUDY SCOPE 22
1.3.1 MARKETS COVERED 22
1.3.2 YEARS CONSIDERED FOR THE STUDY 23
1.4 CURRENCY 23
1.5 LIMITATIONS 23
1.6 MARKET STAKEHOLDERS 23

2 RESEARCH METHODOLOGY 24

2.1 SECONDARY DATA 25
2.1.1 KEY DATA FROM SECONDARY SOURCES 25
2.2 PRIMARY DATA 26
2.2.1 KEY DATA FROM PRIMARIES 27
2.2.2 INSIGHTS FROM INDUSTRY EXPERTS 27
2.3 MARKET SIZE ESTIMATION 28
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 30
2.5 ASSUMPTIONS FOR THE STUDY 31

3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 37

4.1 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS: MARKET OVERVIEW 37
4.2 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018 VS. 2023 (USD BILLION) 38
4.3 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2018 VS. 2023 (USD BILLION) 38
4.4 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC AREA (2018–2023) 39
4.5 GEOGRAPHICAL SNAPSHOT OF THE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 40

5 MARKET OVERVIEW 41

5.1 INTRODUCTION 41
5.2 MARKET DYNAMICS 41
5.2.1 DRIVERS 42
5.2.1.1 Increasing demand for oncology drugs 42
5.2.1.2 Growing demand for antibody-drug conjugates 43
5.2.1.3 Increasing focus of leading pharmaceutical companies on HPAPIs 44
5.2.1.4 Advancements in HPAPI manufacturing technologies 44
5.2.1.5 Growing focus on precision medicine 45
5.2.2 RESTRAINTS 46
5.2.2.1 Requirement of large investments 46
5.2.2.2 Discrepancies in HPAPI banding systems 46
5.2.2.3 Uncertainties associated with products 47
5.2.2.4 High risk of cross-contamination 47
5.2.3 OPPORTUNITIES 47
5.2.3.1 Growing opportunities for CMOs and CDMOs 47
5.2.3.2 Emerging markets 47
5.2.4 CHALLENGES 48
5.2.4.1 Need for appropriate process designs 48
5.2.4.2 Constant evolution of industry standards and technologies 48

6 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS CLASSIFICATION AND OVERVIEW 49

6.1 INTRODUCTION 49
6.2 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS CLASSIFICATION AS PER SAFEBRIDGE CONSULTANTS 49

7 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE 52
7.1 INTRODUCTION 53
7.2 INNOVATIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS 54
7.3 GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS 57

8 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF SYNTHESIS 60
8.1 INTRODUCTION 61
8.2 SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS 62
8.2.1 SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 64
8.2.1.1 Innovative synthetic HPAPIs 65
8.2.1.2 Generic synthetic HPAPIs 67
8.3 BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS 69
8.3.1 BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 71
8.3.1.1 Innovative biotech HPAPIs 72
8.3.1.2 Biosimilars 74
8.3.2 BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 76
8.3.2.1 Monoclonal antibodies 76
8.3.2.2 Vaccines 77
8.3.2.3 Recombinant proteins 78

9 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF MANUFACTURER 79
9.1 INTRODUCTION 80
9.2 CAPTIVE HPAPI MANUFACTURERS 82
9.3 MERCHANT HPAPI MANUFACTURERS 84
9.3.1 MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE 87
9.3.1.1 Innovative merchant HPAPI manufacturers 87
9.3.1.2 Generic merchant HPAPI manufacturers 90
9.3.2 MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS 92
9.3.2.1 Synthetic HPAPIs 92
9.3.2.2 Biotech HPAPIs 94

10 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY THERAPEUTIC APPLICATION 97
10.1 INTRODUCTION 98
10.2 ONCOLOGY 99
10.3 HORMONAL IMBALANCE 101
10.4 GLAUCOMA 104
10.5 OTHER THERAPEUTIC APPLICATIONS 106

11 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY REGION 108
11.1 INTRODUCTION 109
11.2 NORTH AMERICA 110
11.2.1 US 115
11.2.2 CANADA 120
11.3 EUROPE 124
11.3.1 GERMANY 128
11.3.2 FRANCE 133
11.3.3 UK 136
11.3.4 ITALY 140
11.3.5 SPAIN 143
11.3.6 REST OF EUROPE (ROE) 147
11.4 ASIA 151
11.4.1 JAPAN 156
11.4.2 CHINA 160
11.4.3 INDIA 164
11.4.4 REST OF ASIA (ROA) 167
11.5 REST OF THE WORLD (ROW) 172

12 COMPETITIVE LANDSCAPE 177

12.1 OVERVIEW 177
12.2 MARKET RANKING ANALYSIS 178
12.3 COMPETITIVE SITUATION AND TRENDS 180
12.3.1 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 180
12.3.2 MERGERS AND ACQUISITIONS 181
12.3.3 EXPANSIONS 182

13 COMPANY PROFILES 183

(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 PFIZER 183
13.2 NOVARTIS INTERNATIONAL AG 186
13.3 SANOFI 188
13.4 F. HOFFMANN-LA ROCHE 191
13.5 BRISTOL-MYERS SQUIBB 193
13.6 BOEHRINGER INGELHEIM 195
13.7 TEVA PHARMACEUTICAL INDUSTRIES 197
13.8 ELI LILLY AND COMPANY 199
13.9 MERCK 201
13.10 ABBVIE 203
13.11 MYLAN 205
13.12 BAYER 207

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
14 APPENDIX 208

LIST OF TABLES

TABLE 1 PIPELINE OF ONCOLOGY DRUGS (2018) 42
TABLE 2 THERAPEUTIC MONOCLONAL ANTIBODIES APPROVED BY THE FDA IN 2016 43
TABLE 3 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 54
TABLE 4 INNOVATIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY REGION, 2016–2023 (USD MILLION) 55
TABLE 5 NORTH AMERICA: INNOVATIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 55
TABLE 6 EUROPE: INNOVATIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 56
TABLE 7 ASIA: INNOVATIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 56
TABLE 8 GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY REGION, 2016–2023 (USD MILLION) 57
TABLE 9 NORTH AMERICA: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 58
TABLE 10 EUROPE: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 58
TABLE 11 ASIA: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 59
TABLE 12 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016- 2023 (USD MILLION) 61
TABLE 13 SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY REGION, 2016- 2023 (USD MILLION) 62
TABLE 14 NORTH AMERICA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION) 63
TABLE 15 EUROPE: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION) 63
TABLE 16 ASIA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION) 64
TABLE 17 SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2015-2022 (USD MILLION) 64
TABLE 18 INNOVATIVE SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2016- 2023 (USD MILLION) 65
TABLE 19 NORTH AMERICA: INNOVATIVE SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY,
2016- 2023 (USD MILLION) 65
TABLE 20 EUROPE: INNOVATIVE SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION) 66
TABLE 21 ASIA: INNOVATIVE SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION) 66
TABLE 22 GENERIC SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2016- 2023 (USD MILLION) 67
TABLE 23 NORTH AMERICA: GENERIC SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION) 67
TABLE 24 EUROPE: GENERIC SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION) 68
TABLE 25 ASIA: GENERIC SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION) 68
TABLE 26 BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY REGION, 2016- 2023 (USD MILLION) 69
TABLE 27 NORTH AMERICA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION) 70
TABLE 28 EUROPE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION) 70
TABLE 29 ASIA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION) 71
TABLE 30 BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016- 2023 (USD MILLION) 71
TABLE 31 INNOVATIVE BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2016- 2023 (USD MILLION) 72
TABLE 32 NORTH AMERICA: INNOVATIVE BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION) 72
TABLE 33 EUROPE: INNOVATIVE BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION) 73
TABLE 34 ASIA: INNOVATIVE BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION) 73
TABLE 35 BIOSIMILARS MARKET, BY REGION, 2016- 2023 (USD MILLION) 74
TABLE 36 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY,
2016- 2023 (USD MILLION) 74
TABLE 37 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2016- 2023 (USD MILLION) 75
TABLE 38 ASIA: BIOSIMILARS INGREDIENTS MARKET, BY COUNTRY,
2016- 2023 (USD MILLION) 75
TABLE 39 BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2016- 2023 (USD MILLION) 76
TABLE 40 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2016- 2023 (USD MILLION) 77
TABLE 41 VACCINES MARKET, BY REGION, 2016- 2023 (USD MILLION) 77
TABLE 42 RECOMBINANT PROTEINS MARKET, BY REGION, 2016- 2023 (USD MILLION) 78
TABLE 43 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 81
TABLE 44 CAPTIVE HPAPI MANUFACTURERS MARKET, BY REGION,
2016–2023 (USD MILLION) 82
TABLE 45 NORTH AMERICA: CAPTIVE HPAPI MANUFACTURERS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 83
TABLE 46 EUROPE: CAPTIVE HPAPI MANUFACTURERS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 83
TABLE 47 ASIA: CAPTIVE HPAPI MANUFACTURERS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 84
TABLE 48 MERCHANT HPAPI MANUFACTURERS MARKET, BY REGION,
2016–2023 (USD MILLION) 85
TABLE 49 NORTH AMERICA: MERCHANT HPAPI MANUFACTURERS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 85
TABLE 50 EUROPE: MERCHANT HPAPI MANUFACTURERS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 86
TABLE 51 ASIA: MERCHANT HPAPI MANUFACTURERS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 86
TABLE 52 GLOBAL MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016-2023, (USD MILLION) 87
TABLE 53 INNOVATIVE MERCHANT HPAPI MANUFACTURERS MARKET,
BY REGION, 2016–2023 (USD MILLION) 88
TABLE 54 NORTH AMERICA: INNOVATIVE MERCHANT HPAPI MANUFACTURERS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 88
TABLE 55 EUROPE: INNOVATIVE MERCHANT HPAPI MANUFACTURERS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 89
TABLE 56 ASIA: INNOVATIVE MERCHANT HPAPI MANUFACTURERS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 89
TABLE 57 GENERIC MERCHANT HPAPI MANUFACTURERS MARKET, BY REGION,
2016–2023 (USD MILLION) 90
TABLE 58 NORTH AMERICA: GENERIC MERCHANT HPAPI MANUFACTURERS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 90
TABLE 59 EUROPE: GENERIC MERCHANT HPAPI MANUFACTURERS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 91
TABLE 60 ASIA: GENERIC MERCHANT HPAPI MANUFACTURERS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 91
TABLE 61 MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,
2016-2023, (USD MILLION) 92
TABLE 62 MERCHANT SYNTHETIC HPAPI MANUFACTURERS MARKET, BY REGION,
2016–2023 (USD MILLION) 92
TABLE 63 NORTH AMERICA: MERCHANT SYNTHETIC HPAPI MANUFACTURERS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 93
TABLE 64 EUROPE: MERCHANT SYNTHETIC HPAPI MANUFACTURERS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 93
TABLE 65 ASIA: MERCHANT SYNTHETIC HPAPI MANUFACTURERS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 94
TABLE 66 MERCHANT BIOTECH HPAPI MANUFACTURERS MARKET, BY REGION,
2016–2023 (USD MILLION) 94
TABLE 67 NORTH AMERICA: MERCHANT BIOTECH HPAPI MANUFACTURERS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 95
TABLE 68 EUROPE: MERCHANT BIOTECH HPAPI MANUFACTURERS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 95
TABLE 69 ASIA: MERCHANT BIOTECH HPAPI MANUFACTURERS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 96
TABLE 70 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 98
TABLE 71 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2016–2023 (USD MILLION) 99
TABLE 72 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2016–2023 (USD MILLION) 100
TABLE 73 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2016–2023 (USD MILLION) 100
TABLE 74 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2016–2023 (USD MILLION) 101
TABLE 75 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONAL IMBALANCE, BY REGION, 2016–2023 (USD MILLION) 102
TABLE 76 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONAL IMBALANCE, BY COUNTRY, 2016–2023 (USD MILLION) 102
TABLE 77 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONAL IMBALANCE, BY COUNTRY, 2016–2023 (USD MILLION) 103
TABLE 78 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONAL IMBALANCE, BY COUNTRY, 2016–2023 (USD MILLION) 103
TABLE 79 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GLAUCOMA, BY REGION, 2016–2023 (USD MILLION) 104
TABLE 80 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GLAUCOMA, BY COUNTRY, 2016–2023 (USD MILLION) 104
TABLE 81 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GLAUCOMA, BY COUNTRY, 2016–2023 (USD MILLION) 105
TABLE 82 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GLAUCOMA, BY COUNTRY, 2016–2023 (USD MILLION) 105
TABLE 83 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2016–2023 (USD MILLION) 106
TABLE 84 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY,
2016–2023 (USD MILLION) 106
TABLE 85 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION) 107
TABLE 86 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION) 107
TABLE 87 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY REGION, 2016–2023 (USD MILLION) 109
TABLE 88 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 112
TABLE 89 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 112
TABLE 90 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 112
TABLE 91 NORTH AMERICA: MERCHANT HPAPI MANUFACTURERS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 113
TABLE 92 NORTH AMERICA: MERCHANT HPAPI MANUFACTURERS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 113
TABLE 93 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 113
TABLE 94 NORTH AMERICA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 114
TABLE 95 NORTH AMERICA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 114
TABLE 96 NORTH AMERICA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 114
TABLE 97 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 115
TABLE 98 US: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 116
TABLE 99 US: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 116
TABLE 100 US: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016–2023 (USD MILLION) 117
TABLE 101 US: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,
2016–2023 (USD MILLION) 117
TABLE 102 US: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 117
TABLE 103 US: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 118
TABLE 104 US: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION 118
TABLE 105 US: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 119
TABLE 106 US: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 119
TABLE 107 CANADA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 120
TABLE 108 CANADA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 121
TABLE 109 CANADA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016–2023 (USD MILLION) 121
TABLE 110 CANADA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 121
TABLE 111 CANADA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 122
TABLE 112 CANADA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 122
TABLE 113 CANADA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 122
TABLE 114 CANADA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 123
TABLE 115 CANADA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 123
TABLE 116 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 125
TABLE 117 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 125
TABLE 118 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 126
TABLE 119 EUROPE: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016–2023 (USD MILLION) 126
TABLE 120 EUROPE: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 126
TABLE 121 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 127
TABLE 122 EUROPE: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 127
TABLE 123 EUROPE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 127
TABLE 124 EUROPE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 128
TABLE 125 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 128
TABLE 126 GERMANY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 129
TABLE 127 GERMANY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 130
TABLE 128 GERMANY: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016–2023 (USD MILLION) 130
TABLE 129 GERMANY: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 130
TABLE 130 GERMANY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 131
TABLE 131 GERMANY: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 131
TABLE 132 GERMANY: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 131
TABLE 133 GERMANY: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 132
TABLE 134 GERMANY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 132
TABLE 135 FRANCE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 133
TABLE 136 FRANCE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 133
TABLE 137 FRANCE: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016–2023 (USD MILLION) 134
TABLE 138 FRANCE: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 134
TABLE 139 FRANCE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 134
TABLE 140 FRANCE: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 135
TABLE 141 FRANCE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 135
TABLE 142 FRANCE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 135
TABLE 143 FRANCE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 136
TABLE 144 UK: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 137
TABLE 145 UK: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 137
TABLE 146 UK: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016–2023 (USD MILLION) 137
TABLE 147 UK: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,
2016–2023 (USD MILLION) 138
TABLE 148 UK: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 138
TABLE 149 UK: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 138
TABLE 150 UK: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 139
TABLE 151 UK: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2016–2023 (USD MILLION) 139
TABLE 152 UK: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 139
TABLE 153 ITALY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 140
TABLE 154 ITALY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 140
TABLE 155 ITALY: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016–2023 (USD MILLION) 141
TABLE 156 ITALY: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 141
TABLE 157 ITALY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 142
TABLE 158 ITALY: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 142
TABLE 159 ITALY: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 142
TABLE 160 ITALY: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 143
TABLE 161 ITALY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 143
TABLE 162 SPAIN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 144
TABLE 163 SPAIN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 144
TABLE 164 SPAIN: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016–2023 (USD MILLION) 145
TABLE 165 SPAIN: MERCHANT MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,
2016–2023 (USD MILLION) 145
TABLE 166 SPAIN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 145
TABLE 167 SPAIN: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 146
TABLE 168 SPAIN: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 146
TABLE 169 SPAIN: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 146
TABLE 170 SPAIN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 147
TABLE 171 ROE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 148
TABLE 172 ROE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 148
TABLE 173 ROE: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016–2023 (USD MILLION) 148
TABLE 174 ROE: MERCHANT MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS,
2016–2023 (USD MILLION) 149
TABLE 175 ROE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 149
TABLE 176 ROE: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 149
TABLE 177 ROE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 150
TABLE 178 ROE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 150
TABLE 179 ROE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 150
TABLE 180 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY COUNTRY, 2016–2023 (USD MILLION) 153
TABLE 181 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 153
TABLE 182 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 153
TABLE 183 ASIA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016–2023 (USD MILLION) 154
TABLE 184 ASIA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 154
TABLE 185 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 154
TABLE 186 ASIA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 155
TABLE 187 ASIA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 155
TABLE 188 ASIA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 156
TABLE 189 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 156
TABLE 190 JAPAN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 157
TABLE 191 JAPAN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 157
TABLE 192 JAPAN: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016–2023 (USD MILLION) 158
TABLE 193 JAPAN: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 158
TABLE 194 JAPAN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 158
TABLE 195 JAPAN: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 159
TABLE 196 JAPAN: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 159
TABLE 197 JAPAN: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 159
TABLE 198 JAPAN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 160
TABLE 199 CHINA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 161
TABLE 200 CHINA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 161
TABLE 201 CHINA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016–2023 (USD MILLION) 161
TABLE 202 CHINA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 162
TABLE 203 CHINA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 162
TABLE 204 CHINA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 162
TABLE 205 CHINA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 163
TABLE 206 CHINA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 163
TABLE 207 CHINA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 163
TABLE 208 INDIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 164
TABLE 209 INDIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 164
TABLE 210 INDIA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016–2023 (USD MILLION) 165
TABLE 211 INDIA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 165
TABLE 212 INDIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 165
TABLE 213 INDIA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 166
TABLE 214 INDIA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 166
TABLE 215 INDIA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 167
TABLE 216 INDIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 167
TABLE 217 ROA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 168
TABLE 218 ROA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 168
TABLE 219 ROA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016–2023 (USD MILLION) 169
TABLE 220 ROA: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 169
TABLE 221 ROA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 169
TABLE 222 ROA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 170
TABLE 223 ROA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 170
TABLE 224 ROA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 170
TABLE 225 ROA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 171
TABLE 226 ROW: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 173
TABLE 227 ROW: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2016–2023 (USD MILLION) 173
TABLE 228 ROW: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE,
2016–2023 (USD MILLION) 173
TABLE 229 ROW: MERCHANT HPAPI MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 174
TABLE 230 ROW: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2016–2023 (USD MILLION) 174
TABLE 231 ROW: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 175
TABLE 232 ROW: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2016–2023 (USD MILLION) 175
TABLE 233 ROW: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 176
TABLE 234 ROW: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2016–2023 (USD MILLION) 176
TABLE 235 MARKET RANKING ANALYSIS, BY KEY PLAYER, 2017 178
TABLE 236 AGREEMENTS, COLLABORATIONS, PARTNERSHIPS, AND ALLIANCES (2015–2018) 180
TABLE 237 MERGERS AND ACQUISITIONS (2015-2018) 181
TABLE 238 EXPANSIONS (2015–2018) 182
TABLE 239 EXCHANGE RATES (UTILIZED FOR THE CONVERSION OF CHF TO USD) 192

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 24
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 26
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 28
FIGURE 4 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 29
FIGURE 5 DATA TRIANGULATION METHODOLOGY 30
FIGURE 6 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018 VS. 2023 32
FIGURE 7 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2018 VS. 2023 33
FIGURE 8 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2018 VS. 2023 34
FIGURE 9 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2018 VS. 2023 35
FIGURE 10 GEOGRAPHIC SNAPSHOT OF THE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET (2018–2023) 36
FIGURE 11 INCREASING DEMAND FOR ONCOLOGY DRUGS & ANTIBODY-DRUG CONJUGATES—MAJOR FACTOR DRIVING MARKET GROWTH DURING THE FORECAST PERIOD 37
FIGURE 12 INNOVATIVE HPAPIS WILL CONTINUE TO DOMINATE THE GLOBAL MARKET IN 2023 38
FIGURE 13 SYNTHETIC HPAPIS TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2018 38
FIGURE 14 ONCOLOGY SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 39
FIGURE 15 CHINA & INDIA TO REGISTER HIGH GROWTH RATES DURING 2018–2023 40
FIGURE 16 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 41
FIGURE 17 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 53
FIGURE 18 INNOVATIVE HPAPIS SEGMENT TO DOMINATE THE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN 2018 53
FIGURE 19 SYNTHETIC SEGMENT TO DOMINATE THE MARKET IN 2018 61
FIGURE 20 CAPTIVE HPAPI MANUFACTURERS SEGMENT IS EXPECTED TO ACCOUNT FOR LARGEST SHARE OF THE MARKET IN 2018 80
FIGURE 21 NORTH AMERICA TO DOMINATE THE CAPTIVE HPAPI MANUFACTURERS MARKET
IN 2018 81
FIGURE 22 ONCOLOGY SEGMENT TO DOMINATE THE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION (2018) 98
FIGURE 23 ASIA TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2018–2023) 109
FIGURE 24 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT (2018) 111
FIGURE 25 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 124
FIGURE 26 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 152
FIGURE 27 REST OF THE WORLD: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 172
FIGURE 28 KEY DEVELOPMENTS IN THE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2015–2018 177
FIGURE 29 MARKET EVOLUTION FRAMEWORK— AGREEMENTS, COLLABORATIONS, PARTNERSHIPS, AND ALLIANCES FUELED MARKET GROWTH 178
FIGURE 30 BATTLE FOR MARKET SHARE: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS
(2015–2018) 180
FIGURE 31 PFIZER: COMPANY SNAPSHOT (2016) 183
FIGURE 32 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2016) 186
FIGURE 33 SANOFI: COMPANY SNAPSHOT (2017) 188
FIGURE 34 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2017) 191
FIGURE 35 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2016) 193
FIGURE 36 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2016) 195
FIGURE 37 TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT (2017) 197
FIGURE 38 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2016) 199
FIGURE 39 MERCK: COMPANY SNAPSHOT (2016) 201
FIGURE 40 ABBVIE: COMPANY SNAPSHOT (2017) 203
FIGURE 41 MYLAN: COMPANY SNAPSHOT (2017) 205
FIGURE 42 BAYER: COMPANY SNAPSHOT (2017) 207

当レポートのプレスリリースは発行されておりません。